Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors

Annals of Pharmacotherapy

Volumn 45, Issue 10, 2011, Pages

  Lee, Na Ri ^a   Yhim, Ho Young ^a   Yim, Chang Yeol ^a   Kwak, Jae Yong ^a   Song, Eun Kee ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Gastrointestinal stromal tumor; Hyperammonemic encephalopathy; Sunitinib

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ENEMA; FAMOTIDINE; IMATINIB; LACTULOSE; LANSOPRAZOLE; SUNITINIB; TRAMADOL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CASE REPORT; CONFUSION; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENCEPHALOMALACIA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERAMMONEMIA; HYPERAMMONEMIC ENCEPHALOPATHY; INTESTINE PERFORATION; IRRITABILITY; MALE; MESENTERY TUMOR; METASTASIS; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SMALL INTESTINE RESECTION; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC AGENTS; BRAIN DISEASES, METABOLIC; CONFUSION; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPERAMMONEMIA; INDOLES; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRROLES; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 80053977086     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q038     Document Type: Article

References (25)

1. Product information. Sunitinib malate (Sutent). http://www.pfizer.com/files/products/uspi_sutent.pdf (accessed 2010 Jul).
2. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
3. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
4. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
5. Kim DW, Jo YS, Jung HS, et al. An orally administered multi-target tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070-6. DOI 10.1210/jc.2005-2845
6. Papaetis GS, Syrigos KN. Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives. Cancer Metastasis Rev 2010;29:151-70. DOI 10.1007/s10555010-9206-7
7. Nott L, Price TJ, Pittman K, Patterson K, Fletcher J. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma 2007;48:1702-11. DOI 10.1080/10428190701509822
8. Matsumoto K, Sawaki A, Mizuno N, et al. Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor. Jpn J Clin Oncol 2011;41:57-62. DOI 10.1093/jjco/hyq164
9. Liaw CC, Wang HM, Wang CH, et al. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 1999;10:275-81.
10. Davies SM, Szabo E, Wagner JE, Ramsay NK, Weisdorf DJ. Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation. Bone Marrow Transplant 1996;17:1119-25.
11. Blay JY. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol 2010;21:208-15. DOI 10.1093/annonc/mdp291
12. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010;28:2280-5. DOI 10.1200/JCO.2009.27.2757
13. Taran A, Ignatov A, Smith B, Costa SD, Bischoff J. Acute hepatic failure following monotherapy with sunitinib for ovarian cancer. Cancer Chemother Pharmacol 2009;63:971-2. DOI 10.1007/s00280-008-0814-7
14. Mueller EW, Rockey ML, Rashkin MC. Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy 2008;28:1066-70. DOI 10.1592/phco.28.8.1066
15. Cumurciuc R, Martinez-Almoyna L, Henry C, Husson H, de Broucker T. Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol 2008;164:605-7 DOI 10.1016/j.neurol.2008.03.007
16. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
17. Marks A-B, Gerard R, Fournier P, Coupe P, Gautier S. Sorafenib-induced hepatic encephalopathy. Ann Pharmacother 2009;43:2121. DOI 10.1345/aph.1M457
18. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357-71. DOI 10.1007/s00280-009-1170-y
19. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40. DOI 10.2165/00003495-200969020-00006
20. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35:692-706. DOI 10.1016/j.ctrv.2009.08.004
21. Wadzinski J, Franks R, Roane D, Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Board Fam Med 2007;20:499-502. DOI 10.3122/jabfm.2007.05.070062
22. Walker V. Ammonia toxicity and its prevention in inherited defects of the urea cycle. Diabetes Obes Metab 2009;11:823-35. DOI 10.1111/j.1463-1326.2009.01054.x
23. Yoo C, Kim JE, Lee JL, et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 2010;40:980-5. DOI 10.1093/jjco/hyq073
24. Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010;40:194-202. DOI 10.1093/jjco/hyq146
25. Meza-Junco J, Chu QS, Christensen O, et al. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 2009;65:1-4. DOI 10.1007/s00280-009-1096-4